摘要
目的探讨单唾液酸四己糖神经节苷脂(GM1)治疗新生儿缺氧缺血性脑病的临床疗效。方法:48例新生儿缺氧缺血性脑病患儿,随机分为治疗组25例,对照组23例,两组均采用常规治疗,治疗组在常规治疗基础上加用GM1静脉滴注,1次/天,20mg/次,10～14天为一疗程。比较两组患儿治疗前后新生儿神经行为评分(NBNA)及CT测量值。结果:两组患儿治疗5～7天和治疗10～14天NBNA评分有显著差异,且治疗组评分明显高于对照组。两组患儿治疗前和治疗一疗程CT值均无显著差异(P>0.05),出生后28天治疗组CT值明显高于对照组(P<0.05)。结论:GM1治疗新生儿缺氧缺血性脑病疗效显著,未见不良反应发生。
Objective： To investigate the clinical curative effect of monosialotetrahexosylganglioside （GM1） on neonatal hypoxic-ischemic encephalopathy. Methods： Forty-eight cases were randomly divided into two groups, 25 cases in treatment group and 23 cases in control group. Both groups received routine treatment, while GM1 was added in the treatment group 20mg once a day, 10-14 days a course. Neonatal behavior neurological assessment （NBNA） scores and CT values were compared between the two groups before or after treatment. Results： There were statistical differences in NBNA scores between the two groups at 5-7 days and 10-14 days during the treatments, and NBNA scores in treatment group were higher than those in control group. No difference in CT values was found between the two groups before and after treatment. The CT values in the treatment higher than those in the control group at 28 days after birth. Conclusion： GM1 is group were effective in treating neonatal hypoxic-ischemic ence-phalopathy with no toxic reaction.
出处
《药学与临床研究》
2010年第1期67-69,共3页
Pharmaceutical and Clinical Research
关键词
新生儿
缺氧缺血性脑病
神经节苷脂
Neonate
Neonatal hypoxic-ischemic encephalopathy
Monosialotetrahexosylganglioside （GM1）
